9966 — Alphamab Oncology Income Statement
0.000.00%
Last trade - 00:00
- HK$4.51bn
- HK$3.26bn
- CNY218.77m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 146 | 167 | 219 |
Cost of Revenue | |||||
Gross Profit | — | — | 143 | 123 | 164 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 829 | 416 | 545 | 478 | 417 |
Operating Profit | -829 | -416 | -399 | -312 | -198 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -833 | -428 | -412 | -326 | -211 |
Provision for Income Taxes | |||||
Net Income After Taxes | -833 | -428 | -412 | -326 | -211 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -833 | -428 | -412 | -326 | -211 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -833 | -428 | -412 | -326 | -211 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.97 | -0.92 | -0.882 | -0.696 | -0.439 |